NICE rejects Iluvien(Alimera Sciences)for DME treatment

NICE (The National Institute for Health and Clinical Excellence) has now released a draft recommendation that does not back the use of the sustained-release intravitreal implant for the treatment of visual loss caused by chronic Diabetic Macular Edema (DME), NICE did not find the treatment cost-effective. This is a draft appraisal, and NICE expects to issue its final guidance in November. According to Bloomberg, NICE stated that Alimera "underestimated the incremental cost-effectiveness" of Iluvien, adding that: "Unfortunately in this case, the [independent Appraisal Committee] agreed that the evidence provided could not support a positive recommendation